BIOMARIN PHARMACEUTICAL INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 91.48 USD | +2.23% |
|
+1.01% | -4.80% |
ETFs positioned on BioMarin Pharmaceutical Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.45% | 1 M€ | 0.00% | - | |
| 1.79% | 0 M€ | 0.00% | - | |
| 1.59% | 0 M€ | 0.00% | - | |
| 0.83% | 16 M€ | -7.93% | ||
| 0.77% | 4 M€ | +20.15% | ||
| 0.47% | 267 M€ | +6.56% | ||
| 0.44% | 18 M€ | +2.56% | - | |
| 0.20% | 9 M€ | +15.45% | - | |
| 0.19% | 9 M€ | -.--% | - | |
| 0.09% | 736 M€ | +5.48% | ||
| 0.09% | 9 M€ | +0.92% | - | |
| 0.07% | 276 M€ | +11.40% | - | |
| 0.07% | 2,510 M€ | +9.87% | ||
| 0.06% | 9 M€ | +4.69% | - | |
| 0.06% | 0 M€ | 0.00% | - | |
| 0.05% | 7 M€ | +0.11% | - | |
| 0.05% | 277 M€ | -.--% | - | |
| 0.05% | 194 M€ | +4.40% | - | |
| 0.05% | 441 M€ | +8.50% | ||
| 0.04% | 26 M€ | +16.85% | - | |
| 0.04% | 35 M€ | +8.52% | - | |
| 0.04% | 2,658 M€ | +9.21% | - | |
| 0.03% | 205 M€ | -.--% | ||
| 0.03% | 273 M€ | +13.05% | ||
| 0.03% | 206 M€ | -.--% | ||
| 0.03% | 607 M€ | +0.05% | - |
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
2024-04-23
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
89.49
USD
Average target price
110.4
USD
Spread / Average Target
+23.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.80% | 16.98B | |
| -2.68% | 85.68B | |
| +5.53% | 41.4B | |
| -24.67% | 28.22B | |
| +54.82% | 24.64B | |
| -34.20% | 13.29B | |
| -17.76% | 11.66B | |
| -11.43% | 11.65B | |
| -0.37% | 8.18B | |
| +5.35% | 7.78B |
- Stock Market
- Equities
- BMRN Stock
- Funds and ETFs BioMarin Pharmaceutical Inc.
